BrianJBolwellMD

Oncology • Cleveland, OH

Hematologic Oncology

Director, Physician Leadership and Development, Cleveland Clinic

Join to view full profile

Dr. Bolwell is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Bolwell's full profile

Already have an account?

Office
9500 Euclid Ave
Cleveland, OH 44195
Phone+1 800-223-2273

Fax+1 216-444-9774

Summary

What Leadership Books Do Not Tell You : Oncology Times

Everyone is a leader of some sort. As a parent, you may be leading your family on a vacation. As a physician, you may be leading a team of nurses or house staff

Education & Training

University of Pennsylvania Health SystemFellowship, Hematology and Medical Oncology, 1984 - 1987
Case Western Reserve University/University Hospitals Cleveland Medical CenterResidency, Internal Medicine, 1981 - 1984
Case Western Reserve University School of MedicineClass of 1981
Harvard UniversityB.A., 1977

Certifications & Licensure

OH State Medical License 1981 - 2025
PA State Medical License 1984 - 1996
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2006-2014
America's Top Doctors for Cancer Castle Connolly, 2005-2013
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011, 2013
Northern Ohio Live Castle Connolly, 2006-2008
Top MD Consumers Checkbook
Whos Who in Medicine and Healthcare Marquis Whos Who
Join now to see all

Clinical Trials

Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102) Start of enrollment: 2003 Dec 01
Completed
Phase 3
Autologous Stem Cell Transplant in Treating Patients With Progressive or Recurrent Hodgkin's Lymphoma Start of enrollment: 2002 Feb 01
Completed
Phase 2
VP and G-CSF With or Without Rituximab in Autologous Peripheral Stem Cell Transplant For NHL Start of enrollment: 2000 Feb 01
Completed
Not Applicable
Caregiver Support in the Quality of Life of Patients Who Are Undergoing Donor Bone Marrow Transplantation Start of enrollment: 2006 Feb 01
Completed
Caregiver Support in the Coping of Patients Who Are Undergoing a Donor Bone Marrow Transplant Start of enrollment: 2006 Feb 01
Completed
T-Cell Depletion, Donor Hematopoietic Stem Cell Transplant (HSCT), and T-Cell Infusions in Treating Patients With Hematologic Cancer or Other Diseases Start of enrollment: 2004 Jan 01
Terminated
Phase 2
Stem Cell Related Donor Safety Study Start of enrollment: 2010 Jan 01
Completed
Join now to see all

Publications & Presentations

PubMed

9 citations
Therapeutic Dose Monitoring of Busulfan Is Associated with Reduced Risk of Relapse in Non-Hodgkin Lymphoma Patients Undergoing Autologous Stem Cell Transplantation.
Brian T. Hill, Lisa Rybicki, Theresa A. Urban, Mariana Lucena, Deepa Jagadeesh
Biology of Blood and Marrow Transplantation. 2020-02-01
486 citations
Risk factors for acute GVHD and survival after hematopoietic cell transplantation.
Madan Jagasia, Mukta Arora, Mary E.D. Flowers, Nelson J. Chao, Philip L. McCarthy
Blood. 2012-01-05
20 citations
Allogeneic BMT and patient eligibility based on psychosocial criteria: a survey of BMT professionals
Larry Foster, Linda McLellan, Lisa Rybicki, Jane Dabney, Erin Welsh
Bone Marrow Transplantation. 2006-01-01

Journal Articles

Effect of Bone Marrow CD34+Cells and T-cell Subsets on Clinical Outcomes After Myeloablative Allogeneic Hematopoietic Cell Transplantation
Deepa Jagadeesh, Matt Kalaycio, Brian Bolwell, Betty K Hamilton, Brian Hill, Brad Pohlman, Robert Dean, Navneet S Majhail, Sagar S Patel, Rabi Hanna, Aaron T Gerds, Ro..., Nature

Abstracts/Posters

Interactions between Donor Activating Killer Immunoglobulin-like Receptors (KIRs) and Somatic Mutations and Their Association with Outcomes after Allogeneic Hematopoie...
Brian J. Bolwell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

Association of MHC Class I Chain-Related Gene a (MICA) Polymorphisms with Allogeneic Hematopoietic Cell Transplantation Outcomes in Acute Myeloid Leukemia
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
2012 Highlights of ASH in North America (San Francisco, CA)
American Society of Hematology (ASH), San Francisco, California - 2/3/2012

Press Mentions

President Biden’s Cabinet Members Confirmed, HVO Presents Golden Apple Awards, and MoreMay 1st, 2021
Cleveland Clinic Names Dr. Brian Bolwell to New Physician Leadership RoleApril 8th, 2021
How US News' Best Hospitals for Cancer Care Are Improving Patient OutcomesSeptember 8th, 2020
Join now to see all